First Time Loading...

Gilead Sciences Inc
NASDAQ:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
NASDAQ:GILD
Watchlist
Price: 65.42 USD 0.23% Market Closed
Updated: Apr 29, 2024

Gilead Sciences Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gilead Sciences Inc
Operating Income Peer Comparison

Comparables:
ABBV
AMGN
MRNA
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$9.3B
CAGR 3-Years
32%
CAGR 5-Years
2%
CAGR 10-Years
7%
Abbvie Inc
NYSE:ABBV
Operating Income
$16.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
11%
Amgen Inc
NASDAQ:AMGN
Operating Income
$8.2B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
3%
Moderna Inc
NASDAQ:MRNA
Operating Income
-$4.2B
CAGR 3-Years
-77%
CAGR 5-Years
-59%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$3.8B
CAGR 3-Years
10%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
19%

See Also

What is Gilead Sciences Inc's Operating Income?
Operating Income
9.3B USD

Based on the financial report for Dec 31, 2023, Gilead Sciences Inc's Operating Income amounts to 9.3B USD.

What is Gilead Sciences Inc's Operating Income growth rate?
Operating Income CAGR 10Y
7%

Over the last year, the Operating Income growth was -7%. The average annual Operating Income growth rates for Gilead Sciences Inc have been 32% over the past three years , 2% over the past five years , and 7% over the past ten years .